Partilhar
Informação da revista
Os mais lidos
21830
Two years later, azithromycin for COVID-19 and the effect on the heart, is it still relevant?Sérgio Matoso Laranjo
Rev Port Cardiol. 2022;41:557-8
21830
Open access
15351
Documento de Consenso sobre Estratificação de Risco Cardiovascular e estudo da doença coronária em Portugal: a posição dos Grupos de Estudo de Cardiologia Nuclear, Ressonância Magnética e Tomografia Computorizada Cardíaca, de Ecocardiografia e de Fisiopatologia do Esforço e Reabilitação CardíacaNuno Bettencourt, Lígia Mendes, José Paulo Fontes, Pedro Matos, Catarina Ferreira, Ana Botelho, Sofia Carvalho, Anaí Durazzo, ... em nome do GECNRMTC, do GEE e do GEFERC da SPC
Rev Port Cardiol. 2022;41:241-51
15351
Open access
6019
The impact of the COVID-19 pandemic on acute coronary syndrome admissions to a tertiary care hospital in PortugalJoão Calvão, Ana Filipa Amador, Catarina Martins da Costa, Paulo Maia Araújo, Teresa Pinho, João Freitas, Sandra Amorim, Filipe Macedo
Rev Port Cardiol. 2022;41:147-52
6019
Open access
5750
Evaluation of myocardial performance index in patients with COVID-19: An echocardiographic follow-up studyHakan Kaya, Ramazan Asoglu, Abdulmecit Afsin, Hakan Tibilli, Ercan Kurt, Safiye Kafadar, Umut Gulacti, Huseyin Kafadar
Rev Port Cardiol. 2022;41:455-61
5750
Open access
5548
Myocardial T1 mapping with magnetic resonance imaging – a useful tool to understand the diseased heartAndreia S. Gaspar, Sérgio Maltês, Hugo Marques, Rita G. Nunes, António Ferreira
Rev Port Cardiol. 2022;41:61-9
5548
Open access
5214
Is amiodarone still a reasonable therapeutic option for rhythm control in atrial fibrillation?Sérgio Barra, João Primo, Helena Gonçalves, Serge Boveda, Rui Providência, Andrew Grace
Rev Port Cardiol. 2022;41:783-9
5214
Open access
5204
Worrisome trends of ST-elevation myocardial infarction during the Covid-19 pandemic: Data from Portuguese centersLuís Oliveira, Rui Campante Teles, Carina Machado, Sérgio Madeira, Nélson Vale, Carla Almeida, João Brito, Sílvio Leal, ... Miguel Mendes
Rev Port Cardiol. 2022;41:465-71
5204
Open access
4625
ST-elevation myocardial infarction in the Covid-19 pandemic: A step backward in a success storyHenrique Cyrne Carvalho
Rev Port Cardiol. 2022;41:473-4
4625
Open access
4548
Myocardial performance index: Is it time to revisit this old parameter in COVID-19 patients?Ana Teresa Timóteo
Rev Port Cardiol. 2022;41:463-4
4548
Open access
4440
Digital home-based multidisciplinary cardiac rehabilitation: How to counteract physical inactivity during the COVID-19 pandemicRita Pinto, Madalena Lemos Pires, Mariana Borges, Mariana Liñan Pinto, Catarina Sousa Guerreiro, Sandra Miguel, Olga Santos, Inês Ricardo, ... Ana Abreu
Rev Port Cardiol. 2022;41:209-18
4440
Open access
4269
Mavacamten, a novel revolutionizing therapy in hypertrophic obstructive cardiomyopathy: A literature reviewTiago Aguiar, Elisabete Martins
Rev Port Cardiol. 2022;41:693-703
4269
Open access
4145
Remote invasive monitoring of pulmonary artery pressures in heart failure patients: Initial experience in Portugal in the context of the Covid-19 pandemicVera Vaz Ferreira, Tiago Pereira-da-Silva, Duarte Cacela, Rui Cruz Ferreira
Rev Port Cardiol. 2022;41:381-90
4145
Open access
3990
Protocol-based cardiotoxicity monitoring in hydroxychloroquine medicated COVID-19 pediatric patientsInês Hormigo, Tiago Milheiro Silva, Sérgio Laranjo, Conceição Trigo, Ana Margarida Garcia, Catarina Gouveia, Maria João Brito
Rev Port Cardiol. 2022;41:155-63
3990
Open access
3860
Stent-Save a Life international survey on the practice of primary percutaneous coronary intervention during the COVID-19 pandemicHélder Pereira, Christoph Naber, Sandrine Wallace, Tóth Gabor, Sayfollah Abdi, Bagrat Alekyan, Thomas Alexander, Carolina Artucio, ... Jan Piek
Rev Port Cardiol. 2022;41:221-7
3860
Open access
3820
Oral administration of oleuropein and olive leaf extract has cardioprotective effects in rodents: A systematic reviewRafaella Câmara Rocha Menezes, Kathleen Kruger Peres, Marina Tuerlinckx Costa-Valle, Larissa Slongo Faccioli, Eliane Dallegrave, Juliano Garavaglia, Simone Morelo Dal Bosco
Rev Port Cardiol. 2022;41:167-75
3820
Open access
3761
The updated pre-test probability model of the 2019 ESC guidelines improves prediction of obstructive coronary artery diseasePedro M. Lopes, Francisco Albuquerque, Pedro Freitas, Bruno M.L. Rocha, Gonçalo J.L. Cunha, Ana Coutinho Santos, João Abecasis, Sara Guerreiro, ... António M. Ferreira
Rev Port Cardiol. 2022;41:445-52
3761
Open access
3682
Catheter ablation of atrial fibrillation: What we can say after more than 20 years of worldwide experienceMiguel Ventura
Rev Port Cardiol. 2022;41:649-51
3682
Open access
3375
Congenital atrioventricular heart block: From diagnosis to treatmentClara Melim, Joana Pimenta, José Carlos Areias
Rev Port Cardiol. 2022;41:231-40
3375
Open access
3369
NT-proBNP for heart failure diagnosis in Primary Care: Costs or savings? A budget impact studyCândida Fonseca, Paulo Bettencourt, Dulce Brito, Helena Febra, Álvaro Pereira, Victória Genovez, Nelson Lopes
Rev Port Cardiol. 2022;41:183-93
3369
Open access
Conteúdo especial sobre COVID-19
- Clinical outcomes of percutaneous coronary intervention in chronic total occlusion in patients with type 2 diabetes mellitus
- Percutaneous coronary intervention in chronic total occlusions: Should it be avoided in type 2 diabetic patients?
- RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan is the one
- Reply to: RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan is the one
Publicar em
Revista Portuguesa de Cardiologia
A revista pertence ao Committee on Publication Ethics (COPE) www.publicationethics.org e adere aos seus princípios e procedimentos.